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Background: The Reunion Island is a French administrative department located in the Indian Ocean between the islands of
Madagascar and Mauritius. Its population is known to be at a high risk of cystic fibrosis (CF). Methods: Data concerning all CF patients
born at the Reunion Island was extracted from the French CF Registry. Twenty-eight DF508/DF508, 17 Y122X/DF508, and 11 Y122X/
Y122X were included in a genotype–phenotype study. Results: The detection rate of the CFTR mutations was 83% among the CF
patients born at the Reunion Island. Three CFTR mutations accounted for 75% of the detected CF alleles at the Reunion Island (DF508,
Y122X, and 3120 + 1G!A.). The DF508/DF508, DF508/Y122X, and Y122X/Y122X genotypes accounted for 60.2% of the CF
patients. Patients carrying at least one Y122X mutation were pancreatic insufficient, had high sweat chloride values and significantly
lower anthropometric measures. The mean anthropometric values in all three groups were lower that in the whole CF population
followed in ‘‘continental’’ France. This may reflect the poor compliance and even the refusal of treatment noted by the clinicians.
Conclusions: The distribution of CFTR mutations could be explained by the history of the Reunion Island: admixture of French settlers,
African and Asian populations, founder effect and isolation followed by genetic drift. The Y122X allele appears to be associated with a
severe phenotype.
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1. Introduction groups. Furthermore, a large phenotypic diversity is found
between genotypes.Cystic fibrosis (CF) is the most common autosomal
recessive disorder in Caucasian childhood populations. It is
characterised by a chronicle and progressive obstructive
lung disease, pancreatic insufficiency and high sweat
electrolyte levels. Since the CFTR gene was cloned in
1989, more than 1000 mutations have been described
(http://genet.sickkids.on.ca/CFTR). The distribution of
those mutations ranges widely between countries or ethnic1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.03.011
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E-mail address: marc.debraekeleer@univ-brest.fr (M. De Braekeleer).The Reunion Island is a French administrative depart-
ment located in the Indian Ocean between the islands of
Madagascar and Mauritius. Because of its specificity
(history and population constitution), we decided to study
the spectrum of mutations identified in the island and the
genotype–phenotype correlation of the most frequent
mutation (Y122X) using the French Cystic Fibrosis
Registry.2. Materials and methods
Since 1992, the French CF registry has collected and
analysed data from most of the CF patients regularly seen ined by Elsevier B.V. All rights reserved.
Table 1






DeltaF508 78 (53.42) DeltaF508/DeltaF508 22 (32.84)
Y122X 47 (32.19) DeltaF508/Y122X 18 (26.87)
3120 +1G!A 7 (4.79) Y122X/Y122X 13 (19.40)
G542X 2 (1.37) 3120 + 1G!A/3120 + 1G!A 2 (2.99)
3121-3C!G 1 (0.68) DeltaF508/3121-3C!G 1 (1.49)
1161delC 1 (0.68) DeltaF508/2789 + 5G!A 1 (1.49)
1717-1G!A 1 (0.68) DeltaF508/3120 + 1G!A 1 (1.49)
2183AA!G 1 (0.68) DeltaF508/A455E 1 (1.49)
2789 + 5G!A 1 (0.68) DeltaF508/ D993Y 1 (1.49)
993del5 1 (0.68) DeltaF508/ G542X 1 (1.49)
A455E 1 (0.68) DeltaF508/2183AA!G 1 (1.49)
D993Y 1 (0.68) DeltaF508/ G551D 1 (1.49)
G149R 1 (0.68) DeltaF508/1161delC 1 (1.49)
G85E 1 (0.68) Y122X/3120+ 1G!A 1 (1.49)
R1162X 1 (0.68) Y122X/1717-1G!A 1 (1.49)
G551D 1 (0.68) G149R/993del5 1 (1.49)
TOTAL 146 TOTAL 67
Frequencies given in this table are based on the 146 CF chromosomes with
an identified CFTR mutation (detection rate of 83%).
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naire collecting demographic, clinical and social data for
every CF patient seen during that period.
In a first step, we extracted genotypic data on all the
CF patients, born in the Reunion Island, who attended in a
participating care centre anytime between 1994 and 2002.
In a second step, we extracted the available data for all 11
patients homozygous for the Y122X mutation and 17
compound heterozygotes for the Y122X and DF508 muta-
tions, as previously described [1]. Because of the small
size of the CF population, the patients followed at the
Reunion Island (ten Y122X homozygotes and ten com-
pound heterozygotes) were compared to all 20 Reunion
Island patients homozygous for the DF508 mutation. Each
patient followed in a CF care centre in ‘‘continental
France’’ (that is outside the Reunion Island) was matched
to a patient homozygous for the DF508 mutation, of same
sex and age (F 1 year), having consulted in the same CF
care centre. All the data were obtained from the 2000
enquiry (last year available for analysis), except for
clinical events that were compiled during the last 7 years
(1994–2000).
Categorical variables were compared using the chi-
square test or, for small size samples, the Fisher exact
test. Continuous variables were compared by analysis of
variance (ANOVA). A significant level of 5% was used.
Analyses were performed using Epi Info 6.04 FR.3. Results
Eighty-eight CF patients (52 males, 36 females) born in
the Reunion Island have been registered in the French CF
registry since 1994. Eighty-one (92.0%) were alive on
January 1, 2003. The mean and median ages of the living
patients were 11.8 years and 11.0 years, respectively
(range: 0–49 years). Seven died between 1994 and
2002, the mean age at death being 16.0 years (range:
9–20 years).
Mutations were identified for 146 of the 176 CF chro-
mosomes (83.0%) (Table 1). Three accounted for 90.4% of
the identified mutations: DF508 (53.4%), Y122X (32.2%),
and 3120 + 1G!A (4.8%). Thirty CF alleles remained
unknown. Genotypes were fully identified for 67 of the 88
CF patients (76.1%) (Table 1). Three genotypes accounted
for 79.1% of the fully identified genotypes; they were
DF508/DF508 (32.8%), DF508/Y122X (26.9%), and
Y122X/Y122X (19.4%).
Fifty-six patients (28 DF508/DF508, 17 Y122X/DF508,
and 11 Y122X/Y122X) were included in the genotype–
phenotype study (Table 2). The mean age on January 1,
2001 was 12.4 years in the three groups, with median
ages of 11.5, 13.0 and 12.0 years, respectively. One 19-
year-old male homozygous for the DF508 mutation died
of respiratory distress and mellitus diabetes in 2000.
Although the mean age at diagnosis (excluding thosediagnosed prenatally or on familial history and those
neonatally screened) was not statistically different be-
tween all three groups ( p = 0.90), patients homozygous
for the Y122X tended to be diagnosed early, the median
age for this group being much lower than for both other
groups.
Malnutrition and diarrhoea were the major symptoms
leading to diagnosis in all three groups. Meconium ileus
was present in about one fourth of the patients, indepen-
dently of the genotype ( p = 0.950). No statistically signif-
icant difference was found in the mean sweat chloride
concentration ( p = 0.54). All the patients in all three groups
were pancreatic insufficient.
Patients homozygous for the Y122X mutation or com-
pound heterozygous for the Y122X and DF508 mutations
had significantly lower anthropometric measures (height
and weight) than those homozygous for the DF508 muta-
tion. The body mass index (BMI) was also lower, but the
difference was not significant ( p = 0.348).
No significant difference was found in the mean FEV1
and FCV values between the three groups, neither for the
sputum cultures results, but for Haemophilus influenzae.
Pseudomonas aeruginosa was identified in more than half
of the patients. Aspergillus was more frequently identified
in the patients carrying at least one Y122X allele, but the
difference was not significant ( p = 0.08). One 17-year-old
Y122X/DF508 male had a cardiopulmonary transplantation
in 2000. His post-graft FEV1 and FCV values were 85.7%
and 79.4% of the predicted values.
No significant difference was found in the cumulative
clinical events between the 3 groups (diabetes, cirrhosis,
etc.). Nasal polyposis was more frequent among CF
patients carrying at least one Y122X allele compared to
Table 2
Characteristics of patients homozygous for the Y122X mutation, compound heterozygous for the Y122X and DF508 mutations compared to homozygous for
the DF508 mutation (*no significant difference at p= 0.05)
DeltaF508/DeltaF508 Y122X/DeltaF508 Y122X/Y122X p values
Sex (males/females) 20/8 = 28 8/9 = 17 7/4 = 11
Age at 01/01/2001 (years)
Mean ageF SD 12.4F 5.7 12.4F 6.1 12.4F 3.8 *
Median age 11.5 13.0 12.0
Range 3–24 1–23 7–19
Age at diagnosis (months)a
Mean age 31.36F 44.53 32.50F 51.2 24.67F 56.02 *
Median age 7.0 8.0 2.0
Range 0–160 1–159 0–139
Sweat chloride concentration (mEq/l)
Mean valueF SD 106.8F 33.7 119.9F 26.7 107.9F 36.7 *
Median valueF SD 119.0 114.0 99.5
Range 25–179 110–166 68–175
Status at diagnosis
Family history 3 1 1 *
Prenatal diagnosis 0 0 2 0.022
Neonatal screening 3 4 3 *
Meconium ileus 6 (21.4%) 4 (23.5%) 3 (27.3%) *
Dehydration 0 1 0 *
Gastrointestinal symptoms 19 (73.1%) 8 (53.3%) 5 (45.4%) *
Respiratory symptoms 11 (39.2%) 9 (52.9%) 3 (27.3%) *
Nasal polyposis 1 0 0 *
Physical status
Height (Z scoreF SD)  0.572F 1.095  1.007F 1.025  2.164F 1.474 0.002
Weight (Z scoreF SD)  1.180F 1.092  1.621F1.207  2.291F1.451 0.047
BMIF SD (kg/m2) 16.80F 2.45 16.11F1.93 16.23F 2.79 *
Pulmonary status (% of predicted value)
FEV1F SD 73.25F 25.47 62.74F 22.74 80.71F 27.06 *
FVCF SD 80.21F 21.87 66.47F 16.46 80.21F19.37 *
Throat cultures (nr of patients)
Haemophilus influenzae 14 (50.0%) 3 (17.6%) 2 (18.1%) 0.042
Staphylococcus aureus 19 (67.9%) 9 (52.9%) 10 (90.9%) *
Pseudomonas aeruginosa 14 (50.0%) 8 (47.0%) 7 (63.6%) *
Stenotrophomonas maltophilia 2 0 0 *
Burkholderia cepacia 4 1 1 *
Aspergillus 6 (21.4%) 8 (47.1%) 6 (54.5%) 0.080
Candida 2 2 1 *
Clinical events (number of patients)
Cirrhosis 3 (10.7%) 3 (17.6%) 1 (9.1%) *
Mellitus diabetes 3 (10.7%) 1 (5.9%) 1 (9.1%) *
Gallstones 1 0 1 *
Nasal polyposis 4 (14.2%) 6 (36.3%) 4 (36.4%) *
a Excluding patients diagnosed prenatally or on familial history and those neonatally screened.
*p > 0.05.
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( p = 0.18).4. Discussion
The CF birth prevalence is estimated to be close to 1/
1000 live births in the white descent population of theReunion Island [2]. The spectrum of CFTR mutations in
natives of the Reunion Island is dominated by three
mutations: DF508 present on 44.3%, Y122X on 26.7%
and 3120 + 1G!A on 4% of all CFTR chromosomes, for
a total of 75%. The Cystic Fibrosis database maintained at
the Sickkids Hospital in Toronto (Canada) reports that the
world-wide frequency of the DF508 mutation is close to
66% and that the Y122X and 3120 + 1G!A alleles are
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sickkids.on.ca/CFTR).
The Y122X mutation was first described by Chevalier-
Porst et al. [2] in 1992 in a white native patient of the
Reunion Island. They found that 19 of the 66 tested
chromosomes (28.8%) carried the mutation. The Cystic
Fibrosis Genetic Analysis Consortium counted 14 CF chro-
mosomes carrying the Y122X allele, all coming from
France, without specification [3]. In their study on geo-
graphic distribution of 272 cystic fibrosis mutations in
European populations, Estivill et al. [4] counted 20 chro-
mosomes in France, for a frequency in Europe close to
0.07%.
The 3120 + 1G!Awas described by Macek et al. [5] in
African-American patients, in whom it accounts for some
12% of the CF chromosomes. A common ethnic origin of
the mutation in south–east Africa was hypothezised by
Do¨rk et al. [6]. In 1996, Bienvenu et al. [7] described the
3120 + 1G!A mutation to be the third most frequent in the
Reunion Island (12.5%) in comparison with the French
‘‘continental’’ population ( p < 0.001%). Our results show
a much lower prevalence (4.0%). This difference could be
explained by a different ascertainment; we only considered
CF patients born in the Reunion Island although some
patients born in other islands of the Indian Ocean (Mauritius
Island, Mayotte) are also seen in the CF care centres of the
Reunion Island.
The history of the Reunion Island may explain this
particular distribution of CFTR mutations [8]. This small
territory (about 2500 km2) was first populated by French
settlers (46 men and 37 women) in the 17th century. Today,
the population is about 706,300 inhabitants (1999 census),
composed of one half of European ancestry, of which 85%
descent from the first French ‘‘continental’’ settlers, the
other half of African or Oriental ancestry. It is presumed
that the Y122X mutation was present among the first French
settlers, its high frequency being probably the result of a
founder effect and isolation from the mainland, followed by
genetic drift. However, some degree of admixture occurred
with the African population since the 3120 + 1G!A mu-
tation was found in white Caucasian individuals who are the
descendants of the first French settlers (known as ‘‘petits
blancs’’) [9].
This is the first genotype–phenotype correlation study on
the Y122X mutation using a cohort approach. Our results
showed that patients carrying the Y122X allele, either in an
homozygous or compound heterozygous status, have a
severe CF phenotype. The small size of the populations
under study may explain why some differences, although
large, did not reach statistical significance. All the patients
had pancreatic insufficiency, with high sweat chloride andlow anthropometric values. In fact, the mean height, weight
and BMI values in all three groups were lower that in the
whole CF population followed in ‘‘continental’’ France [10].
This may reflect the poor compliance and even the refusal of
treatment noted by the clinicians in several questionnaires
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